DeutschNewstral
Article
jdsupra.com on 2016-07-13 20:55
Amgen and Hospira Square Off Over BPCIA Private Right of Action After Amgen v. Apotex Ruling
Related news
- Amgen Sues Hospira in Fourth Lawsuit Under the BPCIAjdsupra.com
- Apotex Accuses Amgen of Sham BPCIA Litigationjdsupra.com
- Amgen v. Hospira: Amgen Appeals Discovery Rulingjdsupra.com
- Motion to Dismiss Denied in Amgen v. Hospira BPCIAjdsupra.com
- Apotex Takes Aim at Amgen Patent in IPR Petition After Being Sued Under the BPCIAjdsupra.com
- Fed Circuit’s “Amgen v. Apotex” Decision: Clarification of a BPCIA Riddle (Unless, of course, the Supreme Court Steps In)jdsupra.com
- Update: Amgen v. Hospirajdsupra.com
- Apotex Follows the BPCIA “Patent Dance” Againjdsupra.com
- Summary Judgment Practice Scheduled in Amgen v. Hospira Pegfilgrastim Casejdsupra.com
- Federal Circuit affirms Safe Harbor ruling and $70 million award in Amgen Inc. v. Hospira, Inc.jdsupra.com
- Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Rulingjdsupra.com
- The Ripple Effect of the Federal Circuit’s Decision in Amgen v. Apotex on Biosimilar Litigationjdsupra.com
- Amgen v. Hospira: Court Considers Issues Regarding the Scope of Discovery and the RPS’s Ability to Assert Additional Patents in BPCIA Actionsjdsupra.com
- Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotexjdsupra.com
- Amgen v. Hospira Pegfilgrastim Case Stayed Pending Potential Summary Judgment Practicejdsupra.com
- Hospira Opposes Amgen’s PI Motion in Amgen v. Hospirajdsupra.com
- Amgen v. Apotex, Petition for Certiorarijdsupra.com
- Amgen v. Hospira: Amgen Files Appeal Brief at Federal Circuitjdsupra.com
- Hospira Files Responsive Appeal Brief in Amgen v. Hospira Litigationjdsupra.com
- Amgen and AbbVie Settle Adalimumab BPCIA Litigationjdsupra.com